On Apr. 6, 1998, results of the National Cancer Institute’s Breast Cancer Prevention Trial, testing the effectiveness of tamoxifen (Nolvadexﾮ) to prevent the disease, were announced 14 months earlier than expected: women taking tamoxifen had 45% fewer breast cancer diagnoses than women on the placebo, proving that breast cancer can be prevented.